Post by
Tycoon37 on May 22, 2020 12:09pm
Bellus Health Inc. - Chronic Cough is a serious concern
These guys are working on drug(s) for treatment of Chronic Cough. They are Trading at $14 a share on the TSX. They have done a phase 1 and a phase 2 dosing trial. Long ways from becoming an approved drug. Algernon is miles ahead in their potential drug development trading for pennies. I dont know about you but I like my chances with this company just based on this info alone. I like that the CMO has essenitally put over a decade of research collecting a group of drugs (molecules) that he felt had a good chance to be re purposed. I'm not in this name to make pennies. First and foremost I genuinely hope that they can help short term with this pandemic and long term with chronic lung conditions. And secondly I'm going to accumulate and watch. My target price should any of their medications work out is much higher from today's price. If Bellus can trade at $14 why can't Algernon. And if it doesnt well it will make for a decent Tax loss. :O)
(ps I didnt do any kind of DD on Bellus I just came across it and thought it relevant to AGN.)
Happy Trading....
Comment by
DannyDanboy on May 22, 2020 1:24pm
Not to mention Algernon's NP-120 outperformed Bellus Health and Merck's phase 3 compound by 110% - better drug by far.
Comment by
sambelo on May 23, 2020 12:35am
This post has been removed in accordance with Community Policy